BioSpace News Archive

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announced that preliminary clinical results from its first-in-human study of the Amplifi™ Vein Dilation System were presented at the 2021 Vascular Interventional Advances (VIVA) conference.

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct RNA/DNA qPCR Blood Mix.

NextCure, Inc. (Nasdaq: NXTC), today announced the publication of preclinical data in the online journal Frontiers in Immunology, which indicate that collagen fragments produced in cancer can mediate T cell suppression through LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells.

Plexium, Inc., a biotech company focused on discovering and developing protein degrading therapeutics directed towards historically challenging drug targets, announced that company management will present and host one-on-one meetings at the Solebury Trout/BMO Fall Private Company Showcase 2021.

Apollo Endosurgery, Inc. announced preliminary unaudited financial results and corporate updates for the third quarter ended September 30, 2021, including anticipated revenue in the range of $16.0 million to $16.4 million and anticipated revenue growth in the range of 25% to 28% compared to third quarter 2020.

eFFECTOR Therapeutics, a leader in the development of selective translation regulator inhibitors for the treatment of cancer, in collaboration with investigators at Baylor College of Medicine, announced the presentation of new positive data for zotatifin in animal models of triple-negative breast cancer at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

ProfoundBio announces that preclinical data from its novel, proprietary ADC technology platform are being presented at the 2021 Molecular Targets and Cancer Therapeutics conference hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI)

Jaguar Health, Inc. provided updates regarding ongoing research and development related to the company’s crofelemer drug product candidates, and also announced that Dragon SPAC S.p.A. and Napo EU S.p.A., the company’s Italian subsidiary, have submitted the required notification in order to have the impending merger of Dragon SPAC and Napo EU approved as required by Italy’s laws.

The field of medical research has a new tool to develop vaccines, personal immunotherapies, and cures for cancer and other infectious diseases using Full Spectrum Profiling™ (FSP™) technology.

The field of medical research has a new tool to develop vaccines, personal immunotherapies, and cures for cancer and other infectious diseases using Full Spectrum Profiling™ (FSP™) technology.